Evidence map›Paper›PMID 32316502›Full record

ArticleAntibiotics (Basel, Switzerland)2020

Impact of Reappraisal of Fluoroquinolone Minimum Inhibitory Concentration Susceptibility Breakpoints in Gram-Negative Bloodstream Isolates.

Stephanie C Shealy, Matthew M Brigmon, Julie Ann Justo, P Brandon Bookstaver, Joseph Kohn, Majdi N Al-Hasan

Open access · goldAbstract read
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Evaluating outcomes associated with revised fluoroquinolone breakpoints for Enterobacterales urinary tract infections: A retrospective cohort study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2022
    Article
  4. Changing times: The impact of gram-negative breakpoint changes over the previous decade.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2022
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Stephanie C ShealyDepartment of Pharmacy, Prisma Health Richland Hospital, Columbia, SC 29203, USA.
Matthew M BrigmonDepartment of Medicine, Baylor Scott and White, Texas A&M Health Science Center College of Medicine, Temple, TX 76502, USA.
Julie Ann JustoDepartment of Pharmacy, Prisma Health Richland Hospital, Columbia, SC 29203, USA.ORCID 0000-0002-4161-9577
P Brandon BookstaverDepartment of Pharmacy, Prisma Health Richland Hospital, Columbia, SC 29203, USA.ORCID 0000-0002-4409-0963
Joseph KohnDepartment of Pharmacy, Prisma Health Richland Hospital, Columbia, SC 29203, USA.
Majdi N Al-HasanDepartment of Clinical Pharmacy and Outcomes Sciences, University of South Carolina College of Pharmacy, Columbia, SC 29208, USA.ORCID 0000-0001-6501-492X
Prisma Health · USBaylor Medical Center at Garland · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Clinical Laboratory Standards Institute lowered the fluoroquinolone minimum inhibitory concentration (MIC) susceptibility breakpoints for

Indexed as

bacteremiachemotherapeuticsciprofloxacinEscherichia colinon-fermenters/Pseudomonas aeruginosasepsis

Identifiers

PMID32316502
PMCPMC7235854
OpenAlexW3017129251

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.